Trial reportPapillomavirus research (Amsterdam, Netherlands)2019
Two-dose recommendation for Human Papillomavirus vaccine can be extended up to 18 years - updated evidence from Indian follow-up cohort study.
Trial report in Papillomavirus research (Amsterdam, Netherlands), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 15 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Randomised Trial of Two Versus Three Doses of Human Papillomavirus (HPV) Vaccine in India
An Open-Label Clinical Trial Evaluating the Immunogenicity of the 9vHPV Vaccination Regimen Over 6 Months Among Women Aged 16 to 45 Years Old, An Exploratory Immunogenicity Study
Who cites it
15 citing papers in PubMed, 2 syntheses or guidelines pooled it, 32 citations in OpenAlex.
- Effects of human papillomavirus (HPV) vaccination programmes on community rates of HPV-related disease and harms from vaccination.The Cochrane database of systematic reviews · 2025Pooled it
- Cognitions and behaviours of general practitioners in France regarding HPV vaccination: A theory-based systematic review.Preventive medicine · 2021Pooled it
- Faking Death for Cervical Cancer Awareness: Is It Justified?Asian Pacific journal of cancer prevention : APJCP · 2024Article
- Cervical cancer advocacy: needs more than faking death.The Lancet regional health. Southeast Asia · 2024Article
- Article
- Impact of HPV vaccination on HPV-related oral infections.Oral oncology · 2023Article
- Vaccine efficacy against persistent human papillomavirus (HPV) 16/18 infection at 10 years after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre, prospective, cohort study.The Lancet. Oncology · 2021Article
- Contribution of Tata Memorial Centre, India, to cervical cancer care: Journey of two decades.The Indian journal of medical research · 2021Review
- Effective HPV vaccination coverage in Australia by number of doses and two-dose spacing: What if one or two doses are sufficient?Tumour virus research · 2021Article
- Experience of Human Papillomavirus Vaccination Project in a Community Set Up-An Indian Study.Asian Pacific journal of cancer prevention : APJCP · 2021Article
- Effectiveness of HPV vaccination against the development of high-grade cervical lesions in young Japanese women.BMC infectious diseases · 2020Article
- Human Papillomavirus Vaccines: An Updated Review.Vaccines · 2020Review
- Article
- Rationalizing the HPV vaccination schedule: A long road to a worthwhile destination.Papillomavirus research (Amsterdam, Netherlands) · 2019Article
- Human papillomavirus vaccine use in clinical practice - What dermatologists should know as health care providers.Indian journal of sexually transmitted diseases and AIDSReview
Corrections and comments
- Commented on by
Authors and funding
40 authors at 13 institutions in 3 countries.
Funding
Abstract
Earlier publication from the ongoing multi-centric study of the International Agency for Research on Cancer to evaluate less than three doses of the quadrivalent Human Papillomavirus (HPV) vaccine in India amongst unmarried girls demonstrated non-inferior total antibody titres, neutralizing antibody titres and antibody avidity in 2-dose recipients compared to 3-dose recipients at 15-18 years of age (Bhatla et al., 2018) [7]. The number of participants recruited at 15-18 years of age was 1515 and 1795 in the 3-dose and the 2-dose groups respectively. At a median follow-up of 7 years, incident HPV 16/18 infections were detected in 1.6% women receiving two doses and 0.8% women receiving three doses at 15-18 years. Frequency of incident infection was 7.0% in the age- and site-matched unvaccinated women (N = 1484). No persistent infection from HPV 16 was observed in the 2- or 3-dose recipients and one (0.2%) persistent HPV 18 infection was documented, each in the 3-dose and 2-dose cohorts. Among the unvaccinated women, the frequency of HPV 16/18 persistent infection was 1.7%. The protection offered by two doses of quadrivalent HPV vaccine against incident and persistent infections in recipients at 15-18 years is comparable to that seen in 3-dose recipients at 15-18 years.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.